Tumor Immunology: Multidisciplinary Science Driving Combination Therapy
joint with Antibodies as Drugs: Immunological Scaffolds as Therapeutics
Organizer(s): Elizabeth M. Jaffee and Axel HoosDate: February 08 - 13, 2015
Location: Fairmont Banff Springs, Banff, AB, Canada
The field of cancer immunotherapy is evolving rapidly as a result of key scientific and developmental principles that have been discovered in recent years. New technologies together with this new knowledge have given birth to the next generation of vaccines, adoptive cellular therapies and T cell modulating agents, all of which are being investigated in preclinical models and in patients. This new era has also revealed the complex network of signaling pathways within the tumor microenvironment that currently favors the pro-carcinogenic process, but new evidence also demonstrates that this process can be altered with agents that modulate these pathways resulting in antitumor immunity. Much is being learned about the interdependency of these pathways with each other and with the non-immune cellular components within the tumor microenvironment that include the tumor, epithelial and endothelial cells, and the stroma. Thus, optimizing outcomes for patients will likely come from successfully combining immunotherapies with each other and with other classes of therapies. This will require the integration of different scientific approaches ranging from small molecule targeted therapies to complex biologics, as well as addressing molecular pathways in all of the cell subtypes within the tumor microenvironment. This conference brings together experts from academia and industry who have pioneered these areas of immunologic science, and will showcase the integration of this increasingly complicated knowledge into rapid translation into clinical applications.
Scholarship Deadline: October 9 2014
Discounted Abstract Deadline: October 9 2014
Abstract Deadline: November 12 2014
Discounted Registration Deadline: December 9 2014
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
BioNTech RNA Pharmaceuticals GmbH
Immatics Biotechnologies GmbH
Janssen R&D: Pharmaceutical Companies of Johnson & Johnson
Regeneron Pharmaceuticals, Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: